Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 4/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.38 |
| ▸ | CYCS | P99999 | 4/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | TERT | O14746 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10050505 | 0.96 | MAPT (0.41) | TOP1ABCG2MAPTKMT2A | |
| SCHEMBL10050506 | 0.89 | TERT (0.46) | TOP1ABCG2CYCSENPP2MAPT | |
| SCHEMBL10050512 | 0.86 | TERT (0.43) | TOP1ABCG2MAPTTERTKMT2A | |
| SCHEMBL10050508 | 0.86 | MAPT (0.43) | ABCG2MAPT | |
| SCHEMBL10050500 | 0.81 | MAPT (0.39) | ABCG2MAPT | |
| SCHEMBL12265142 | 0.81 | TOP1 (0.41) | TOP1ABCG2CYCSENPP2MAPK1 | |
| SCHEMBL10050490 | 0.78 | TERT (0.37) | TOP1ABCG2ENPP2MAPTTERT | |
| SCHEMBL9230080 | 0.73 | TOP1 (0.60) | TOP1ABCG2CYCSENPP2MAPT | |
| SCHEMBL2549051 | 0.73 | TOP1 (0.60) | TOP1ABCG2CYCSENPP2MAPT | |
| SCHEMBL15580410 | 0.71 | TOP1 (0.34) | TOP1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8092661-B2 | Electropolymerisable monomers, soluble in an aqueous solution and comprising a metalloporphyrin | BIOMERIEUX (FR) | 2012-01-10 | — | — | US | disclosed |
| US-8092661-B2 | Electropolymerisable monomers, soluble in an aqueous solution and comprising a metalloporphyrin | BIOMERIEUX (FR) | 2012-01-10 | — | — | US | disclosed |
| US-20090314660-A1 | Novel Electropolymerisable Monomers, Soluble in an Aqueous Solution and Comprising a Metalloporphyrin | BIOMERIEUX (FR) | 2009-12-24 | — | — | US | disclosed |
| US-20090314660-A1 | Novel Electropolymerisable Monomers, Soluble in an Aqueous Solution and Comprising a Metalloporphyrin | BIOMERIEUX (FR) | 2009-12-24 | — | — | US | disclosed |
| WO-2007051947-A1 | NOVEL ELECTROPOLYMERISABLE MONOMERS WHICH ARE SOLUBLE IN AN AQUEOUS SOLUTION AND COMPRISE A METALLOPORPHYRINE | BIOMERIEUX (FR) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090314660-A1 | Novel Electropolymerisable Monomers, Soluble in an Aqueous Solution and Comprising a Metalloporphyrin | EPS15, PPOX, ACR | TOP1 4796/4885ABCG2 703/4885CYCS 2450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.